

FlexTouch: A Prefilled Insulin Pen with a Novel Injection Mechanism with Consistent High Accuracy at Low- (1 U), Medium- (40 U), and High- (80 U) Dose Settings

Jakob Oest Wielandt, B.Sc., M.Sc.,¹ Marcus Niemeyer, Ph.D.,² Marianne Rye Hansen,¹ Ditlef Bucher, M.Sc.,¹ and Niels Bjerrum Thomsen, M.Sc., Ph.D.¹

Abstract

Background:

FlexTouch[®] is the only prefilled insulin pen that utilizes an easy touch button that does not extend at any dose in place of a push-button extension. Rigorous testing has shown that the new FlexTouch pen accurately and consistently delivers insulin doses.

Methods:

This study assessed dose accuracy of FlexTouch, KwikPen[®], and SoloSTAR[®]. Dose accuracy for minimum, medium, and maximum doses of each pen type (1, 40, and 80 U for FlexTouch and SoloSTAR and 1, 30, and 60 U for KwikPen) was assessed.

Results:

FlexTouch delivered all doses consistently, as demonstrated by low standard deviations. FlexTouch showed similar accuracy to KwikPen at 1 U and to SoloSTAR at 40 and 80 U. However, FlexTouch was significantly more accurate at delivering 1 U of insulin than SoloSTAR ($p < .0001$).

Conclusions:

This study demonstrates that FlexTouch, a new prefilled pen, delivers insulin accurately and consistently at low, medium, and high doses. In addition, FlexTouch is currently the only prefilled pen that has a push button that does not extend at any dose, making FlexTouch easier to use than other pens.

J Diabetes Sci Technol 2011;5(5):1195-1199

Author Affiliations: ¹Novo Nordisk A/S, Hillerød, Denmark; and ²Novo Nordisk A/S, Søborg, Denmark

Abbreviations: (ISO) International Organization for Standardization

Keywords: accuracy, diabetes, FlexTouch, insulin, prefilled pen

Corresponding Author: Marcus Niemeyer, Ph.D., Novo Nordisk A/S, Vandtårnsvej 114, DK-2860 Søborg, Denmark; email address MCNY@novonordisk.com